These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15790802)

  • 1. Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib.
    Brinker A; Nourjah P
    Am J Health Syst Pharm; 2005 Apr; 62(7):739-43. PubMed ID: 15790802
    [No Abstract]   [Full Text] [Related]  

  • 2. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.
    Brinker A; Goldkind L; Bonnel R; Beitz J
    Drugs Aging; 2004; 21(7):479-84. PubMed ID: 15132714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice.
    Cutts C; LaCaze A; Tett S
    Br J Clin Pharmacol; 2002 Nov; 54(5):522-7. PubMed ID: 12445032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.
    Florin TH
    Med J Aust; 2004 Mar; 180(6):310-2; author reply 311-2. PubMed ID: 15012575
    [No Abstract]   [Full Text] [Related]  

  • 5. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
    Schnitzer TJ; Kong SX; Mitchell JH; Mavros P; Watson DJ; Pellissier JM; Straus WL
    Clin Ther; 2003 Dec; 25(12):3162-72. PubMed ID: 14749154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.
    Kivitz AJ; Greenwald MW; Cohen SB; Polis AB; Najarian DK; Dixon ME; Moidel RA; Green JA; Baraf HS; Petruschke RA; Matsumoto AK; Geba GP;
    J Am Geriatr Soc; 2004 May; 52(5):666-74. PubMed ID: 15086644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2 inhibitors still eyed for cancer prevention.
    Thompson CA
    Am J Health Syst Pharm; 2005 May; 62(9):890, 894. PubMed ID: 15851492
    [No Abstract]   [Full Text] [Related]  

  • 8. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
    Fredy J; Diggins DA; Morrill GB
    Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Side effects cause enormous costs. Expensive arthritis therapy].
    MMW Fortschr Med; 2001 Nov; 143(46):60. PubMed ID: 11759607
    [No Abstract]   [Full Text] [Related]  

  • 10. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.
    Nelson MR
    Med J Aust; 2004 Feb; 180(3):140. PubMed ID: 14748681
    [No Abstract]   [Full Text] [Related]  

  • 11. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
    Henderson P
    JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939848
    [No Abstract]   [Full Text] [Related]  

  • 12. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
    Bierma-Zeinstra SM; Bohnen AM; Berger MY; Thomas S
    JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939847
    [No Abstract]   [Full Text] [Related]  

  • 13. Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors.
    Behan K; Cutts C; Tett SE
    Eur J Clin Pharmacol; 2005 Mar; 61(1):55-8. PubMed ID: 15785961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis.
    Simon LS; Zhao SZ; Arguelles LM; Lefkowith JB; Dedhiya SD; Fort JG; Johnson KE
    Clin Ther; 1998; 20(6):1218-35; discussion 1192-3. PubMed ID: 9916614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
    Weaver AL; Messner RP; Storms WW; Polis AB; Najarian DK; Petruschke RA; Geba GP; Tershakovec AM
    J Clin Rheumatol; 2006 Feb; 12(1):17-25. PubMed ID: 16484875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS; Nourjah P; Grosser SC; Graham DJ
    Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee.
    Makarowski W; Weaver A; Rubin B; Caldwell J; McMahon FG; Noveck RJ; Lee D; Offenberg H; Sack M; Sikes D; Trapp R; Rush S; Kuss M; Ganju J; Bocanegra TS; Ratliff JM
    Clin Ther; 1996; 18(1):114-24. PubMed ID: 8851458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy.
    Bouée S; Charlemagne A; Fagnani F; Le Jeunne P; Sermet C; Naudin F; Lancry PJ
    Joint Bone Spine; 2004 May; 71(3):214-20. PubMed ID: 15182793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.
    Bardou M; Barkun AN; Ghosn J; Hudson M; Rahme E
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):880-7. PubMed ID: 15476151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
    Gibofsky A
    J Hypertens Suppl; 2002 Sep; 20(6):S25-30. PubMed ID: 12683424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.